NEW YORK, Sept. 20, 2005 (PRIMEZONE) -- Taglich Brothers, Inc. announces it initiated coverage of Neurologix, Inc. (OTCBB:NRGX).
Neurologix, Inc. is a development-stage biotechnology company. Its most advanced gene therapy candidate is NLX-P101, which recently completed the accrual phase of Phase I human clinical trial to treat Parkinson's disease (PD). Its pipeline also includes preclinical gene therapy product candidates for the treatment of epilepsy (NLX-E201) and the treatment of Huntington's disease (NLX-H301), as well as a candidate in the discovery stage for the treatment of Alzheimer's disease.
The complete 28-page report is available at www.taglichbrothers.com.
Taglich Brothers, Inc. is a full-service broker dealer focused exclusively on microcap companies. The company defines the microcap segment of the equity market as companies with less than $250 million in market capitalization. Taglich Brothers currently offers institutional and retail brokerage services, investment banking and comprehensive research coverage to the investment community.
NOTE: The information and statistical data contained herein have been obtained from sources, which we believe to be reliable but in no way are warranted by us as to accuracy or completeness. We do not undertake to advise you as to change in figures or our views. This is not a solicitation of any order to buy or sell. Taglich Brothers, Inc. is fully disclosed with its clearing firm, Pershing, LLC, is not a market maker and does not sell to or buy from customers on a principal basis. The above mentioned research report is the opinion of Taglich Brothers, Inc. and is not a guarantee that the target price for the stock will be met or that predicted business results for the company will occur. There may be instances when fundamental, technical and quantitative opinions contained in above mentioned research report are not in concert. We, our affiliates, any officer, director or stockholder or any member of their families may from time to time purchase or sell any of the above-mentioned or related securities. Analysts and members of the Research Department are prohibited from buying or selling securities issued by the companies that Taglich Brothers, Inc. has a research relationship with, except if ownership of such securities was prior to the start of such relationship, then an analyst or member of the Research Department may sell such securities after obtaining expressed written permission from the Director of Research. As of the date of above mentioned research report, As of the date of this report, Michael Taglich, President, owns 2,500 shares of Neurologix and Robert Taglich, Managing Director, owns 2,500 shares of Neurologix. All research issued by Taglich Brothers, Inc. is based on public information. Taglich Brothers, Inc. does not currently have an Investment Banking relationship with the company and was not a manager or co-manager of any offering for the company within the last three years. The company paid a retainer of $5,000 (USD) on June 2005, and upon publication will pay a monthly monetary fee of $1,750 (USD) to Taglich Brothers, Inc. for the creation and dissemination of research reports.